LON:DXRX

Diaceutics (DXRX) Share Price, News & Analysis

Diaceutics logo
GBX 182 -8.00 (-4.21%)
As of 11/20/2026 12:33 PM Eastern

About Diaceutics Stock (LON:DXRX)

Advanced

Key Stats

Today's Range
182
▼
195
50-Day Range
158.55
▼
206.50
52-Week Range
125
▼
210
Volume
465,131 shs
Average Volume
298,615 shs
Market Capitalization
£154.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 215
Consensus Rating
Buy

Company Overview

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Diaceutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

DXRX MarketRank™: 
1.35832521908 of 5 stars

Diaceutics scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Diaceutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Diaceutics has a consensus price target of GBX 215, representing about 18.1% upside from its current price of GBX 182.

  • Amount of Analyst Coverage

    Diaceutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Diaceutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Diaceutics is -568.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Diaceutics is -568.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Diaceutics has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for DXRX.
  • Dividend Yield

    Diaceutics does not currently pay a dividend.

  • Dividend Growth

    Diaceutics does not have a long track record of dividend growth.

  • News Sentiment

    Diaceutics has a news sentiment score of -0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Diaceutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Diaceutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought GBX 0 in company stock and sold £4,940,000 in company stock.

  • Percentage Held by Insiders

    26.23% of the stock of Diaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    32.18% of the stock of Diaceutics is held by institutions.

  • Read more about Diaceutics' insider trading history.
Receive DXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DXRX Stock News Headlines

Diaceutics (LON:DXRX) Stock: Insider Jordan Clark Sells 250,000 Shares
Are Tesla and SpaceX Going Bankrupt?
Tesla and SpaceX shares crashed right after Democrats took the House and the Senate in the midterm election. Elon Musk backed President Trump and donated millions to Republicans, and many believe he will become a political target. Brownstone Research founder Jeff Brown has seen Musk's new technology on camera. He says he is more convinced than ever that nothing can stop the coming Elon Musk revolution.tc pixel
Diaceutics (LON:DXRX) Insider Sells £475,000 in Stock
Canaccord Genuity Group Reaffirms Buy Rating for Diaceutics (LON:DXRX)
Diaceutics (LON:DXRX) Stock Falls 1.4% - Here's Why
See More Headlines

DXRX Stock Analysis - Frequently Asked Questions

Diaceutics' stock was trading at GBX 128 on January 1st, 2026. Since then, DXRX shares have increased by 42.2% and is now trading at GBX 182.

Diaceutics PLC (LON:DXRX) issued its earnings results on Tuesday, September, 22nd. The company reported GBX (3.27) earnings per share for the quarter. Diaceutics had a negative net margin of 0.66% and a negative trailing twelve-month return on equity of 0.68%.

Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Company Calendar

Last Earnings
9/22/2026
Today
11/21/2026

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
LON:DXRX
CIK
N/A
Phone
N/A
Fax
N/A
Employees
151
Year Founded
N/A

Price Target and Rating

High Price Target
GBX 215
Low Price Target
GBX 215
Potential Upside/Downside
+18.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
GBX (0.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-£2.84 million
Net Margins
-0.66%
Pretax Margin
N/A
Return on Equity
-0.68%
Return on Assets
-6.06%

Debt

Debt-to-Equity Ratio
5.40
Current Ratio
2.55
Quick Ratio
9.92

Sales & Book Value

Annual Sales
£41.33 million
Price / Sales
3.74
Cash Flow
GBX 58.34 per share
Price / Cash Flow
3.12
Book Value
GBX 45.87 per share
Price / Book
3.97

Miscellaneous

Outstanding Shares
84,972,000
Free Float
N/A
Market Cap
£154.65 million
Optionable
Not Optionable
Beta
0.88
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (LON:DXRX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners